SAMPLE EVALUATION A retrospective Vantage read on a public company — the facts shown are drawn from public FDA, SEC, ClinicalTrials.gov, and other public records, so you can check it yourself. This is an abbreviated teaser, not a full report on this company.
The Vantage Index · Retrospective Sample · Public Company

Sample Evaluation — Guardant Health

Retrospective · public company · facts checkable against public records. A diligence read of knowable, cited facts — not a forecast of outcomes.

VerticalDiagnostic · Oncology
TechnologyBlood-based testing (liquid biopsy)
ApplicationsGenomic profiling & cancer screening
Public RecordNASDAQ: GH
Reviewed By
Arvind Ravinutala, MD  ·  Aswini Ravinutala, BME
Retrospective Sample
Numeric composite & per-domain confidence bands
in the full report
The Vantage Index TL;DR: a commercial-stage liquid-biopsy diagnostics company with an FDA-approved screening test and a fully traceable public record — read here against real, checkable diligence risks, not a forecast.
Chapter 1

The Vantage Index: Summary Read

A retrospective, high-level read on a public company — assembled the way a full Vantage report is: from primary public records, with factual claims cited to their sources. The numeric composite and per-domain confidence bands live in the full report; the qualitative read is below.

Guardant Health presents as a commercial-stage liquid-biopsy diagnostics company. Its core offering is comprehensive genomic profiling of advanced solid tumors from a routine blood draw — a non-invasive alternative to a tissue biopsy — and it has additionally brought a blood-based colorectal cancer screening test through to FDA approval. It is a publicly traded company (NASDAQ: GH), so its regulatory and financial record is on the public record and independently checkable. The specific clearance and approval numbers and dates are left out of this teaser.

A disciplined diligence read is not a cheerleader. Even on a company with an approved screening test, the risks that genuinely exist are worth naming: reimbursement and payer-coverage dependence, a competitive liquid-biopsy field, and screening-test adoption and performance scrutiny. Those are covered in Chapter 3 as risk considerations — qualitatively, and without invented numbers.

In the full report
  • The specific FDA clearance and approval numbers and dates
  • Numeric Vantage Index composite with a credible interval
  • Per-domain scores with confidence bands across all eight domains
  • Named comparable companies and what their public records show
  • Factual claims footnoted to their public sources
Chapter 2

The Vantage Index: Domain Findings

Every full Vantage report scores eight domains. This teaser shows a high-level qualitative read per domain with one grounded, publicly checkable sentence each. Regulatory, Clinical, and Competitive are shown a little more fully; the rest are locked more tightly. Scores, citations, and confidence bands are in the full report.

Regulatory
Summary
A blood-based colorectal cancer screening test that received FDA approval, alongside genomic-profiling assays — a diagnostics regulatory record that sits on the public record.
Full domain analysis, the specific FDA clearance/approval numbers and dates, citations, and confidence band — in the full report.
Clinical
Summary
Clinical evidence for liquid-biopsy profiling and blood-based screening is registered on ClinicalTrials.gov and independently checkable.
Full domain analysis, trial-level evidence and ClinicalTrials.gov identifiers, citations, and confidence band — in the full report.
Competitive
Summary
Liquid biopsy is a competitive, well-capitalized field; positioning against other blood-based testing entrants is the central watch item.
Full domain analysis, the named competitor cohort and positioning read, citations, and confidence band — in the full report.
Reimbursement
Summary
Diagnostics adoption depends heavily on payer coverage and coding; reimbursement is a genuine watch item for both profiling and screening.
Full domain analysis, CMS coverage/coding read and payer evidence base, citations, and confidence band — in the full report.
Commercial
Summary
Screening-test adoption and uptake — moving a new blood-based screen into routine practice — is an open commercial question.
Full domain analysis, market and adoption record, citations, and confidence band — in the full report.
IP
Summary
Assay chemistry and bioinformatics underpin the platform; the durability of that protection is the diligence question.
Full domain analysis, the patent family and USPTO identifiers, freedom-to-operate read, citations, and confidence band — in the full report.
Financial
Summary
A publicly traded company (NASDAQ: GH) with a fully traceable financial and SEC-filing record.
Full domain analysis, SEC filing-level detail and the financial trajectory, citations, and confidence band — in the full report.
Team
Locked
This teaser does not surface operating-team detail; the full report reads the operating team's public record.
Full domain analysis, operating-team assessment and prior-company track record, citations, and confidence band — in the full report.
Chapter 3

The Vantage Index: Risk Considerations

The point of a diligence read is that it flags real risks even on a strong company. These are stated qualitatively, from the knowable public picture — no invented numbers, no forecast of outcomes.

Reimbursement and payer-coverage dependence

Diagnostics revenue turns on payer coverage and coding. Dependence on reimbursement decisions is a genuine consideration a diligence read surfaces for any testing company, independent of how coverage ultimately settles.

A competitive liquid-biopsy field

Blood-based cancer testing is an area many well-capitalized players pursue. Competitive intensity in the liquid-biopsy field is a real consideration for any platform addressing the same clinical need.

Screening-test adoption and performance scrutiny

A new blood-based screen faces both adoption friction and close scrutiny of real-world performance. Adoption pace and performance scrutiny are standard, material considerations a diligence read names explicitly rather than assumes away.

In the full report
  • Each risk paired with the evidence that would change the reading, and cited comparables where the record has them
  • Reassessment triggers: the specific data points that would change the reading
  • Cross-lens stress tests — physician (MD) and biomedical engineer (BME) on each finding

See this on a company you're evaluating.

This is an abbreviated teaser, not a full report on this company. A full Vantage report includes cited sources, per-domain confidence bands and comparable companies.

Run one on a deal you're evaluating → Talk to Arvind, MD
Illustrative sample on a public company for demonstration. Vantage makes no predictive claims; this is a diligence read of knowable, cited facts, not a forecast of outcomes. Guardant Health is a public company; the facts shown here are drawn from public FDA, SEC, ClinicalTrials.gov, and other public records and are stated at a deliberately high level in this teaser. Specific identifiers, numbers, and dates are left out of this teaser. Guardant Health is not a Vantage client, and this sample is not affiliated with or endorsed by Guardant Health, Inc.